Capital Markets & Financing
国家医保局公布《谈判药品续约规则》
The National Medical Insurance Administration of China announced Negotiating Drug Contract Renewal Rules.
US Plans Narrow China Tech Investment Limits, Likely by 2024
The Biden administration’s plans to restrict investments in China will be narrowly focused on cutting-edge technology and only new investments.
China issues draft to ease rules on foreign investment in asset management firms
China issues draft to ease rules on foreign investment in asset management firms.
Biotech’s optimism is returning amid signs of a better second half and a brighter 2024
Endpoints projects a brighter 2024 for biotechnology companies.
Leerink Partners reborn after Jeff Leerink acquires SVB Securities
Leerink Partners reborn after Jeff Leerink acquires SVB Securities.
Healthcare-focused investment firm Vertex Ventures HC launches $200m Fund III
Vertex Ventures HC (VVHC) has launched a $200 million Fund III to support life sciences and medical technology companies.
Kelun-Biotech Raises HK$1.26 Billion in Hong Kong IPO; Prices at Bottom of Range
Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) priced its Hong Kong initial public offering on Monday to raise HK$1.26 billion in net proceeds from the offering.
Wall Street Banks Court Sovereign Funds for Syngenta’s $9 Billion IPO
Wall Street banks are helping approach international investors for Syngenta Group's 65 billion yuan ($9 billion) initial public offering in Shanghai.
Chinese biopharmaceutical firm Pyrotech Therapeutics bags $97m in Series A round
Chinese biopharmaceutical firm Pyrotech Therapeutics has secured 700 million yuan ($97.2 million) in a Series A financing round co-led by state-owned investment firms SDIC Venture Capital and China Venture Capital, according to a company release on Monday
Regulatory logjam in China offshore listings hits firms’ funding plans
Chinese companies are finding it challenging to get timely regulatory approvals for overseas share offerings as scrutiny of their proposals has intensified under new listing rules, frustrating potential issuers and investment bankers.
